2000
DOI: 10.1128/jvi.74.18.8494-8501.2000
|View full text |Cite
|
Sign up to set email alerts
|

Patterns of Changes in Human Immunodeficiency Virus Type 1 V3 Sequence Populations Late in Infection

Abstract: We have used a V3-specific heteroduplex tracking assay (V3-HTA) with probes from two different human immunodeficiency virus type 1 (HIV-1) subtypes to examine the extent and pace of HIV-1 evolution late in infection. Twenty-four subjects with advanced HIV-1 infection (CD4 ؉ T-cell count, <100/l) and stable viral loads were studied using blood plasma samples collected over a study period of approximately 9 months, during which time most of the subjects were treated with reverse transcriptase inhibitors. The V3-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
37
0

Year Published

2001
2001
2016
2016

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 35 publications
(38 citation statements)
references
References 37 publications
(22 reference statements)
1
37
0
Order By: Relevance
“…These numbers are similar to those seen in subjects from the placebo arm of the same trial (20). The V3-HTA patterns were less complex than the V1/V2-HTA patterns, with 6 of 13 subjects having a single V3 variant and 7 subjects having two to three V3 variants at trial entry, again similar to the placebo arm of the trial (26).…”
Section: Characterization Of Virus Populations At Trial Entrysupporting
confidence: 67%
“…These numbers are similar to those seen in subjects from the placebo arm of the same trial (20). The V3-HTA patterns were less complex than the V1/V2-HTA patterns, with 6 of 13 subjects having a single V3 variant and 7 subjects having two to three V3 variants at trial entry, again similar to the placebo arm of the trial (26).…”
Section: Characterization Of Virus Populations At Trial Entrysupporting
confidence: 67%
“…For determination of whether the CD4-independent viruses from different patients were preexistent in the viral isolates from the ARRP and for examination of the relative abundance of the CD4-independent variants, heteroduplex tracking assays (HTA) were performed as previously described (18,25). Briefly, viral RNA was isolated from culture supernatants and used in RT-PCR to generate 400-bp V1/V2 or 144-bp V3 products.…”
Section: Methodsmentioning
confidence: 99%
“…Some products were cloned into the pT7Blue-3 vector by use of the Perfectly Blunt cloning kit (Novagen). Clones were screened by HTA and sequenced as described previously (25).…”
Section: Methodsmentioning
confidence: 99%
“…K03455] in standard reference HXB2) very frequently distinguish primary X4 from R5 viruses (9,15,16,21,42,66), with positions 24 and 27 implicated in some cases (10,37). However, while evolutionary studies of the R5-X4 transition have been undertaken (30,38,61,62), the actual mutational pathway or pathways by which R5 viruses that establish infections in vivo evolve into X4 viruses (i.e., the specific evolutionary sequence of mutations required) has been largely unexplored. It is not clear whether the appearance of basic amino acids at sites 11 and 25 is sufficient or even necessary in most cases in vivo to lead to the outgrowth of X4 virus or whether, instead, a more gradual process of mutation accumulation takes place.…”
mentioning
confidence: 99%
“…If mutant accumulation does occur in a more gradual process, this may provide an opportunity for both early detection and arrest of X4 development. Viruses that can use both coreceptors (R5X4 viruses) are known to arise around the time of R5-to-X4 transition (2,8,38,61), but their evolutionary role in that transition is not certain. The answers to questions of in vivo evolution cannot be approached by phenotypic assays alone, and analyses based on the appearance of positively charged mutations at V3 sites 11 and 25 have led to incomplete and sometimes ambiguous conclusions regarding the transition process (35).…”
mentioning
confidence: 99%